FDG PET, and circulating tumour HPV DNA during chemoRadiotherapy In p16-positive AnaL squamous cell carcinoma: The IMPERIAL study Read More

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma Read More

A randomized phase II trial - Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer Read More

Open-label, single-arm, signal-seeking phase II study of the combination of durvalumab and olaparib in advanced cholangiocarcinoma after initial chemotherapy and durvalumab (BIL-PPP). Read More

STOPNET - Comparison of patient outcomes with or without continuation of somatostatin injections after the commencement of Peptide Receptor Radionuclide Therapy (PRRT) Read More

BIOMARCER-2 - Biomarker informed optimal management of advanced RAS wild type colorectal cancer in right sided disease Read More

This is an open-label, randomised, prospective, multi-centre registry-based trial evaluating the impact of delivering all active cytotoxic agents during initial systemic therapy, by way of an alternating treatment schedule versus standard of care, on outcomes in treatment-naïve mCRC. Read More

This translational study aims to determine what impact STING levels have on the ability for gastro-oesophageal cancers to respond to treatment, how this impacts the immune response to cancer and ultimately the ability to survive. Read More

The OMEGCA study is a prospective trial to develop a sensitive assay to detect clinically occult peritoneal metastases. Read More

Predicting ChemoRadiotherapy Sensitivity in Rectal Cancer Organoids (PRoSecCO) Read More